— We have everything you need: full data on over 800 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker.

Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker.

Both vaccines are mRNA based, made by Moderna and Pfizer. Here’s how they compare with each other. Judge rules Trump unlawfully invoked Alien Enemies Act against alleged Tren de Aragua members ...

The Pfizer and Moderna options deliver genetic instructions for the body to temporarily make copies of the protein. In contrast, the Novavax vaccine uses lab-grown copies of the spike protein ...

Pfizer has an Earnings ESP of -7.23% and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Per our proven model, companies with the ...

Pfizer PFE will report its first-quarter earnings on April 29, before market open. The Zacks Consensus Estimate for sales and earnings for the first quarter is pegged at $13.88 billion and 67 ...

A made-in-Hamilton COVID vaccine that requires no needles is moving to the next stage of testing and researchers are looking for volunteers to take part. The vaccine that is inhaled instead of ...

If you’re on the fence about investing in Amicus Therapeutics, Inc., Moderna or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

“I think it wins at summary judgment because it’s not complicated. If, for example, Pfizer or CVS is the only one federally licensed to sell a Schedule III product in a state, and your state is ...

What's interesting about Pfizer stock is that the company has been punished for its own success. In 2020, it generated $41.9 billion in full-year sales, with no revenue from COVID-19 treatments.

A panel of advisers to the Centers for Disease Control and Prevention on Wednesday recommended lowering the age at which some people can receive a vaccine for respiratory syncytial virus, but stopped ...